Additional information
| Active substance | Tamoxifen Citrate |
|---|---|
| Active Half-Life | 5-7 days |
| Classification | SERM |
| Dosage | 20-40 mg/day |
| Acne | No |
| Water Retention | No |
| HBR | No |
| Hepatotoxicity | No |
| Aromatization | No |
| Lab Test | See Document |
| Also known as | Tamoxifen |
| WAREHOUSE | International Warehouse 3 |
| Blood pressure | Generally does not affect blood pressure |
| Trade name | Nolvadex |
| Storage conditions | Store at room temperature, away from moisture and heat |
| Chemical name | (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine |
| Formula | C26H29NO |
| Substance class | Selective Estrogen Receptor Modulator (SERM) |
| Main action | Antiestrogen |
| Half-life | 5 to 7 days |
| Dosage (medical) | 20 mg per day |
| Dosage (sports) | 10-20 mg per day |
| Effects | Reduces estrogen binding to receptors, prevents gynecomastia, promotes a more favorable hormone balance for testosterone |
| Side effects | Hot flashes, vaginal dryness or discharge, mood swings, nausea, headache |
| Use in sports | Used to combat gynecomastia and improve the testosterone to estrogen ratio |
| Manufacturer | BELIGAS |
Reviews
There are no reviews yet.